Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma

Abstract Objectives Beta-blocker use is associated with improved survival for multiple nonurologic malignancies. Our objective was to evaluate the association between beta-blocker use and survival among surgically managed hypertensive patients with clear-cell renal cell carcinoma (ccRCC). Methods Hy...

Full description

Saved in:
Bibliographic Details
Published in:Urologic oncology 2017, Vol.35 (1), p.36.e1-36.e6
Main Authors: Parker, William P., M.D, Lohse, Christine M., M.S, Zaid, Harras B., M.D, Cheville, John C., M.D, Boorjian, Stephen A., M.D, Leibovich, Bradley C., M.D, Thompson, R. Houston, M.D
Format: Article
Language:English
Subjects:
Adrenergic beta-Antagonists - therapeutic use
Aged
Antihypertensive Agents - therapeutic use
Beta-blocker
Carcinoma, Renal Cell - complications
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - surgery
Cause of Death
Disease Progression
Disease-Free Survival
Female
Follow-Up Studies
Humans
Hypertension
Hypertension - complications
Hypertension - drug therapy
Kidney Neoplasms - complications
Kidney Neoplasms - mortality
Kidney Neoplasms - surgery
Male
Middle Aged
Nephrectomy
Proportional Hazards Models
Renal cell carcinoma
Retrospective Studies
Survival
Survival Rate
United States - epidemiology
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objectives Beta-blocker use is associated with improved survival for multiple nonurologic malignancies. Our objective was to evaluate the association between beta-blocker use and survival among surgically managed hypertensive patients with clear-cell renal cell carcinoma (ccRCC). Methods Hypertensive patients with ccRCC treated with either radical or partial nephrectomy between 2000 and 2010 were identified from our Nephrectomy Registry. Beta-blocker use within 90 days before surgery was identified. The associations between beta-blocker use and risk of disease progression, death from renal cell carcinoma (RCC), and all-cause mortality were assessed using Cox proportional hazards regression models. Results In total, 913 hypertensive patients were identified who underwent either partial or radical nephrectomy for ccRCC. Of these, 104 (11%) had documented beta-blocker use within 90 days before surgery. At last follow-up (median 8.2 y among survivors), 258 patients showed progression (median 1.6 y following surgery), and 369 patients had died (median 4.1 y following surgery), including 138 who died of RCC. After adjusting for PROG (progression-free survival) and SSIGN (cancer-specific survival) scores, beta-blocker use was not significantly associated with the risk of disease progression (hazard ratio [HR] = 0.94; 95% CI: 0.61–1.47; P = 0.80) or the risk of death from RCC (HR = 0.74; 95% CI: 0.38–1.41; P = 0.35). Similarly, on multivariable analysis adjusting for clinicopathologic features, there was not a significant association between beta-blocker use and the risk of all-cause mortality (HR = 0.83; 95% CI: 0.59–1.16; P = 0.27). Conclusions Beta-blocker use for hypertension within 90 days before surgery was not associated with the risk of progression, death from RCC, or death from any cause.
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2016.08.013